ICBS acquires 30% interest in Bacteria...( NEW YORK and MONTREAL Oct. 30 / I...)

NEW YORK and MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - ICBS Limited (PINKSHEETS: ICBM), today announced the acquisition of 30% interest in Bacteria Bank Ltd.

Bacteria Bank Ltd., is a Bio medical company that owns over ten thousand cryogenically stored bacteria for use in medical research, located in Montreal Canada. The company is headed by Dr. Karl Weiss a world renowned bacteriologist.

Dr. Karl Weiss is a Microbiologist and Infectious Diseases Specialist at Maisonneuve-Rosemont Hospital in Montreal . He is also Associate Clinical Professor at the Faculty of Medicine at University of Montreal , and the director of pharmacological research at Maisonneuve-Rosemont hospital. He is also an associate member of the division of infectious diseases at the Jewish General Hospital in Montreal , and an adjunct-professor of Medicine at McGill University.

Bacteria bank has a unique collection of over 10,000 frozen bacteria which can be used for many different purposes.

1. susceptibility testing of potentially promising anti-microbial

agents developed by biotech companies or researchers in

universities.

2. susceptibility testing of new antibiotics against specific and

emerging pathogens such as MRSA ( Methicillin resistant

Staphyloccocus aureus), VRE ( Vancomycin Resistant Enterococcus).

3. susceptibility testing against a wide array of Gram negative

agents ( E. coli, Salmonella, shigella, and other gastro-

intestinal pathogens responsible for million of deaths every year

in the world)

4. susceptibility testing of new agents against Streptococcus

pneumoniae responsible for the majority of sinusitis, otitis

media, pneumonia and some forms of bronchitis. In North America

only, there are over 300 million of antibiotic prescriptions in

the outpatients setting, and S.pneumoni
'/>"/>